NICE has recommended interim funding on England’s NHS for AstraZeneca’s ovarian cancer drug Lynparza in the earlier stages of the disease as a maintenance treatment after an initial round o
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
